MacroGenics Inc (MGNX) stock
MGNXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.17−0.03 (-1.36%)
Close on Nov 16, 2026Market cap $138.23MP/E –Yield –
MacroGenics r&d expenses
Research and development expenses are spending on new products and technology.
MacroGenics's R&D Expenses for the twelve months ending Jun 30, 2026 was $140.44M, down 12.2% year over year. For fiscal 2025 it was $147.17M, down 16.9% from the year before. Over ten years it grew 4.1% a year on average. The highest annual figure on record is $214.58M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $147.17M | -16.9% |
| FY2024 | Dec 31, 2024 | $177.19M | +6.4% |
| FY2023 | Dec 31, 2023 | $166.58M | -19.5% |
| FY2022 | Dec 31, 2022 | $207.03M | -3.5% |
| FY2021 | Dec 31, 2021 | $214.58M | +11.1% |
| FY2020 | Dec 31, 2020 | $193.20M | -1.1% |
| FY2019 | Dec 31, 2019 | $195.31M | +2.3% |
| FY2018 | Dec 31, 2018 | $190.83M | +29.6% |
| FY2017 | Dec 31, 2017 | $147.23M | +20.6% |
| FY2016 | Dec 31, 2016 | $122.09M | +24.2% |
| FY2015 | Dec 31, 2015 | $98.27M | +40.0% |
| FY2014 | Dec 31, 2014 | $70.19M | +50.7% |
| FY2013 | Dec 31, 2013 | $46.58M | +2.5% |
| FY2012 | Dec 31, 2012 | $45.43M | +10.6% |
| FY2011 | Dec 31, 2011 | $41.09M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $38.78M | -4.9% |
| Q1 FY2026 | Mar 31, 2026 | $34.97M | -11.9% |
| Q4 FY2025 | Dec 31, 2025 | $33.97M | -12.6% |
| Q3 FY2025 | Sep 30, 2025 | $32.71M | -19.3% |
| Q2 FY2025 | Jun 30, 2025 | $40.79M | -21.1% |
| Q1 FY2025 | Mar 31, 2025 | $39.70M | -13.8% |
| Q4 FY2024 | Dec 31, 2024 | $38.89M | -17.9% |
| Q3 FY2024 | Sep 30, 2024 | $40.54M | +34.6% |
| Q2 FY2024 | Jun 30, 2024 | $51.73M | +19.7% |
| Q1 FY2024 | Mar 31, 2024 | $46.03M | +0.3% |
| Q4 FY2023 | Dec 31, 2023 | $47.35M | +3.7% |
| Q3 FY2023 | Sep 30, 2023 | $30.13M | -37.5% |
| Q2 FY2023 | Jun 30, 2023 | $43.23M | -16.5% |
| Q1 FY2023 | Mar 31, 2023 | $45.87M | -25.3% |
| Q4 FY2022 | Dec 31, 2022 | $45.65M | -18.3% |
| Q3 FY2022 | Sep 30, 2022 | $48.19M | -3.3% |
| Q2 FY2022 | Jun 30, 2022 | $51.74M | -7.2% |
| Q1 FY2022 | Mar 31, 2022 | $61.44M | +15.7% |
| Q4 FY2021 | Dec 31, 2021 | $55.85M | +32.0% |
| Q3 FY2021 | Sep 30, 2021 | $49.82M | +11.6% |
| Q2 FY2021 | Jun 30, 2021 | $55.78M | -2.7% |
| Q1 FY2021 | Mar 31, 2021 | $53.12M | +8.6% |
| Q4 FY2020 | Dec 31, 2020 | $42.30M | -18.6% |
| Q3 FY2020 | Sep 30, 2020 | $44.66M | -0.4% |
| Q2 FY2020 | Jun 30, 2020 | $57.35M | +11.5% |
| Q1 FY2020 | Mar 31, 2020 | $48.89M | +3.9% |
| Q4 FY2019 | Dec 31, 2019 | $51.96M | +10.7% |
| Q3 FY2019 | Sep 30, 2019 | $44.85M | -3.0% |
| Q2 FY2019 | Jun 30, 2019 | $51.44M | -1.1% |
| Q1 FY2019 | Mar 31, 2019 | $47.06M | +3.0% |
| Q4 FY2018 | Dec 31, 2018 | $46.93M | +20.4% |
| Q3 FY2018 | Sep 30, 2018 | $46.22M | +12.8% |
| Q2 FY2018 | Jun 30, 2018 | $52.01M | +50.9% |
| Q1 FY2018 | Mar 31, 2018 | $45.67M | +39.2% |
| Q4 FY2017 | Dec 31, 2017 | $38.99M | +25.3% |
| Q3 FY2017 | Sep 30, 2017 | $40.98M | +35.3% |
| Q2 FY2017 | Jun 30, 2017 | $34.46M | – |
| Q1 FY2017 | Mar 31, 2017 | $32.80M | – |
| Q4 FY2016 | Dec 31, 2016 | $31.11M | – |
| Q3 FY2016 | Sep 30, 2016 | $30.30M | – |
See a number that looks wrong?